> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Backs Novo Nordisk Diabetes Drug
- URL: https://www.fdaweb.com/panel-backs-novo-nordisk-diabetes-drug/
- Published: 2017-10-19T12:00:00.000Z
- Updated: 2026-09-14T22:57:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139912

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has voted 16-0 to recommend approval of Novo Nordisk’s once-weekly semaglutide to improve glycemic control in adults with Type 2 diabetes. In a [briefing document](https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM580460.pdf?ref=fdaweb.com) released in advance of the meeting, agency reviewers said the indication of semaglutide as an adjunct to diet and exercise to improve glycemic control is supported by efficacy data. “Both doses of semaglutide (0.5 mg and 1.0 mg) demonstrated superiority to placebo, in terms of change in HbA1c from baseline, in a monotherapy trial as well as in atrial with basal insulin background therapy (Table 6),” FDA reviewers noted. “Both doses of semaglutide also demonstrated superiority to active comparators sitagliptin and insulin glargine for the HbA1c primary endpoint. Semaglutide 1.0 mg also demonstrated superiority to exenatide ER.”